SCYNEXIS

$7.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.51%) Today

$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SCYNEXIS and other stocks, options, and ETFs commission-free!

About SCYX

SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

CEO

Marco Taglietti

Employees

Headquarters

Jersey City, New Jersey

Founded

1999

Market Cap

168.44M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

247.32K

High Today

$7.88

Low Today

$7.65

Open Price

$7.88

Volume

299.78K

52 Week High

$10.40

52 Week Low

$4.20

Analyst Ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

SCYX Earnings

-$3.78

-$2.52

-$1.26

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 10, Pre-Market